Jorge S Reis-Filho

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi request reprint P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Pathol Res Pract 199:785-93. 2003
  2. ncbi request reprint EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
    J S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 209:445-53. 2006
  3. ncbi request reprint FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    Jorge Sergio Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 12:6652-62. 2006
  4. pmc The impact of expression profiling on prognostic and predictive testing in breast cancer
    J S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Clin Pathol 59:225-31. 2006
  5. ncbi request reprint Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue
    Jorge S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 19:307-19. 2006
  6. ncbi request reprint The molecular genetics of breast cancer: the contribution of comparative genomic hybridization
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Pathol Res Pract 201:713-25. 2005
  7. ncbi request reprint Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    J Pathol 207:1-13. 2005
  8. ncbi request reprint Metaplastic breast carcinomas are basal-like tumours
    J S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Histopathology 49:10-21. 2006
  9. pmc Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
    Jorge S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 7:R1028-35. 2005
  10. pmc FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007

Detail Information

Publications73

  1. ncbi request reprint P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Pathol Res Pract 199:785-93. 2003
    ..Caution should be exercised when translating the results of studies performed on cell lines to human neoplasms...
  2. ncbi request reprint EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
    J S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 209:445-53. 2006
    ..2...
  3. ncbi request reprint FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    Jorge Sergio Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 12:6652-62. 2006
    ..However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets...
  4. pmc The impact of expression profiling on prognostic and predictive testing in breast cancer
    J S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Clin Pathol 59:225-31. 2006
    ..Although the results are promising, further optimisation and standardisation of the technique and properly designed clinical trials are required before microarrays can reliably be used as tools for clinical decision making...
  5. ncbi request reprint Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue
    Jorge S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 19:307-19. 2006
    ..Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis...
  6. ncbi request reprint The molecular genetics of breast cancer: the contribution of comparative genomic hybridization
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Pathol Res Pract 201:713-25. 2005
    ..CGH has been instrumental in dissecting distinct molecular pathways toward breast malignancy and in establishing a direct relationship between genotype and clinical pathological features...
  7. ncbi request reprint Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    J Pathol 207:1-13. 2005
    ..Taken together, these data suggest that at least some PLCs may evolve from the same precursor or through the same genetic pathway as classic lobular carcinomas...
  8. ncbi request reprint Metaplastic breast carcinomas are basal-like tumours
    J S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Histopathology 49:10-21. 2006
    ..Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype...
  9. pmc Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
    Jorge S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 7:R1028-35. 2005
    ..We investigated whether HER2 and EGFR overexpression was present and evaluated gene amplification in a series of metaplastic breast carcinomas...
  10. pmc FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007
    ..Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line...
  11. ncbi request reprint Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 106:181-9. 2007
    ....
  12. doi request reprint Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 88:491-503. 2008
    ..The 17q12 amplicon is complex and harbours multiple genes that may be associated with breast cancer development and progression, and potentially exploitable as therapeutic targets...
  13. ncbi request reprint Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis
    Kay Savage
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 13:90-101. 2007
    ....
  14. doi request reprint Functional characterization of EMSY gene amplification in human cancers
    Paul M Wilkerson
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 225:29-42. 2011
    ..Taken together, this suggests that EMSY is unlikely to be a driver of the 11q13-q14 amplicon and does not have a dominant role in modulating the response to agents targeting cells with defective homologous recombination...
  15. ncbi request reprint DNA amplifications in breast cancer: genotypic-phenotypic correlations
    Kai Keen Shiu
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW36JB, UK
    Future Oncol 6:967-84. 2010
    ....
  16. doi request reprint Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 220:562-73. 2010
    ..This proof-of-principle study provides direct evidence of intra-tumour genetic heterogeneity in breast cancers, and shows that in some cases morphological diversity may be underpinned by distinct genetic aberrations...
  17. doi request reprint Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type
    Magali Lacroix-Triki
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:282-98. 2010
    ..Both components of mixed mucinous tumours are remarkably similar at the molecular level to pure mucinous cancers, suggesting that mixed mucinous carcinomas may be best classified as variants of mucinous cancers rather than of IDC-NSTs...
  18. doi request reprint Breast cancer molecular profiling with single sample predictors: a retrospective analysis
    Britta Weigelt
    Cancer Research UK, London Research Institute, London, UK
    Lancet Oncol 11:339-49. 2010
    ..Three microarray-based single sample predictors (SSPs) have been used to define molecular classification of individual samples. We aimed to establish agreement between these SSPs for identification of breast cancer molecular subtypes...
  19. ncbi request reprint Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 87:75-83. 2007
    ..For accurate results using Phi29 amplification, samples subjected to aCGH analysis should be combined with reference DNA amplified with the same method, using similar amounts of starting template...
  20. ncbi request reprint Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis
    Jorge S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 19:999-1009. 2006
    ..The results of this study confirm the association between cyclin D1 overexpression and positivity for hormone receptors and the lack of CCND1 amplification in basal-like breast carcinomas...
  21. doi request reprint PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
    Maryou B Lambros
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 23:1334-45. 2010
    ..Co-amplification of PPM1D and HER2/TOP2A and CCND1 are not random events and may suggest the presence of a 'firestorm' genetic profile...
  22. doi request reprint Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study
    Konstantin J Dedes
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
    Breast Cancer Res Treat 124:653-66. 2010
    ..CTTN expression is not associated with the outcome of breast cancer patients treated with anthracycline-based chemotherapy...
  23. pmc Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    J Pathol 232:553-65. 2014
    ..Although seemingly private genetic events, some of the fusion transcripts found in MPCs may play a role in maintenance of a malignant phenotype and potentially offer therapeutic opportunities...
  24. doi request reprint Breast cancer precursors revisited: molecular features and progression pathways
    Maria A Lopez-Garcia
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, UK
    Histopathology 57:171-92. 2010
    ....
  25. doi request reprint A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 118:481-98. 2009
    ..e., gains of 1q, 8q and 20q), basal-like and luminal cell lines are characterised by distinct genomic aberrations...
  26. doi request reprint CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification
    Pamela Klingbeil
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 120:95-109. 2010
    ..Given that expression of CD44 is not an absolute requirement for the survival of cells harbouring CD44 gene amplification, CD44 is unlikely to be a driver of the 11p13 amplicon...
  27. doi request reprint PPM1D is a potential therapeutic target in ovarian clear cell carcinomas
    David S P Tan
    Department of Histopathology and Gynecologic Oncology, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 15:2269-80. 2009
    ..To identify therapeutic targets in ovarian clear cell carcinomas, a chemoresistant and aggressive type of ovarian cancer...
  28. doi request reprint Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers
    Daniel Wetterskog
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    J Pathol 226:84-96. 2012
    ..Breast AdCCs constitute an entity distinct from grade-matched and triple-negative and basal-like IDC-NSTs, emphasizing the importance of histological subtyping of triple-negative and basal-like breast carcinomas...
  29. doi request reprint Tiling path genomic profiling of grade 3 invasive ductal breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Clin Cancer Res 15:2711-22. 2009
    ....
  30. ncbi request reprint Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
    David S P Tan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 111:27-44. 2008
    ....
  31. doi request reprint A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK
    J Pathol 227:29-41. 2012
    ....
  32. pmc Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Rd, London SW3 6JB, UK
    J Natl Cancer Inst 103:662-73. 2011
    ..The aim of this study was to determine the objectivity and interobserver reproducibility of the assignment of molecular subtype classes by hierarchical cluster analysis...
  33. doi request reprint β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
    Felipe C Geyer
    Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 24:209-31. 2011
    ..In conclusion, β-catenin/Wnt pathway activation is preferentially found in triple-negative/basal-like breast carcinomas, is associated with poor clinical outcome and is unlikely to be driven by CTNNB1 mutations in breast cancer...
  34. pmc Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data
    Anita Grigoriadis
    Ludwig Institute for Cancer Research University College London Breast Cancer Laboratory, 91 Riding House Street, London, W1W 7BS, UK
    Breast Cancer Res 8:R56. 2006
    ....
  35. pmc MYC amplification in breast cancer: a chromogenic in situ hybridisation study
    S Maria Rodriguez-Pinilla
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Clin Pathol 60:1017-23. 2007
    ....
  36. pmc FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:2085-94. 2010
    ..Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance...
  37. doi request reprint Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components
    Caterina Marchio
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 218:301-15. 2009
    ....
  38. pmc Functional characterization of the 19q12 amplicon in grade III breast cancers
    Rachael Natrajan
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 14:R53. 2012
    ..The aim of this study was to identify the genes within the 19q12 amplicon whose expression is required for the survival of cancer cells harbouring their amplification...
  39. doi request reprint Non-existence of caveolin-1 gene mutations in human breast cancer
    Neill Patani
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 131:307-10. 2012
    ..Taken together with other studies, which have also failed to identify CAV1 mutations, our data call into question the existence and biological and clinical relevance of CAV1 gene mutations in human breast cancer...
  40. doi request reprint Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection
    Lucia Hernandez
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 227:42-52. 2012
    ....
  41. pmc Integrated functional, gene expression and genomic analysis for the identification of cancer targets
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 4:e5120. 2009
    ..In conclusion, this strategy represents a novel and effective strategy for the identification of functionally important therapeutic targets in cancer...
  42. doi request reprint PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
    Konstantin J Dedes
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, SW3 6JB London, UK
    Sci Transl Med 2:53ra75. 2010
    ..Given that up to 80% of endometrioid endometrial cancers lack PTEN expression, our results suggest that PARP inhibitors may be therapeutically useful for a subset of endometrioid endometrial cancers...
  43. pmc A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF
    Steven Whittaker
    Signal Transduction Team, Section of Cell and Molecular Biology, Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:8036-44. 2010
    ..As expected, the growth rate in vivo of a wild-type BRAF human tumor xenograft model is unaffected by inhibitor 1t. In contrast, 1t elicits significant therapeutic responses in mutant BRAF-driven human melanoma xenografts...
  44. doi request reprint β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast
    Magali Lacroix-Triki
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 23:1438-48. 2010
    ..catenin nuclear expression should not be used as a single marker to differentiate fibromatosis from other spindle cell tumours of the breast...
  45. doi request reprint Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas
    Maria A Lopez-Garcia
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:64-75. 2010
    ....
  46. doi request reprint An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 121:575-89. 2010
    ..g. proliferation, HER2 and ER signalling) may be driven by specific patterns of copy number aberrations...
  47. doi request reprint Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation
    Charlotte B Westbury
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 219:131-40. 2009
    ..The findings are relevant to both fibrosis and atrophy occurring after radiotherapy for early breast cancer...
  48. doi request reprint Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Histopathology 55:732-43. 2009
    ..The aim of this study was to determine whether MGA is clonal and whether it harbours chromosomal aberrations similar to those found in matched invasive ductal carcinoma of no special type (IDC-NST)...
  49. ncbi request reprint Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation
    Afshan McCarthy
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    J Pathol 219:306-16. 2009
    ..This mouse model of Lkb1 deficiency provides a potentially useful tool to investigate the role of Lkb1 in tumourigenesis and to guide the development of therapeutic approaches...
  50. doi request reprint Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Mod Pathol 23:951-60. 2010
    ....
  51. ncbi request reprint Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue
    Peter T Simpson
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 202:274-85. 2004
    ..This analysis demonstrates the utility of 14-3-3sigma as a new adjunct antibody for characterization of myoepithelial cells and myoepithelial lesions and it may be a novel prognostic factor for breast cancer patients...
  52. ncbi request reprint Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models
    Lorenzo Melchor
    Division of Breast Cancer Research, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 233:124-37. 2014
    ..This is a fundamental advance in our understanding of tumour aetiology...
  53. ncbi request reprint Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization
    Maryou B K Lambros
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 86:398-408. 2006
    ..In summary, this protocol enables the generation of probes mapping to any gene of interest that can be applied to FFPETS, allowing correlation of morphological features with gene copy number...
  54. ncbi request reprint High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma
    Tarek M A Abdel-Fatah
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, London, UK
    Am J Surg Pathol 31:417-26. 2007
    ..Molecular studies are being performed to substantiate the hypothesis that tubular and lobular carcinomas have direct evolutionary links to CCLs and flat epithelial atypia...
  55. ncbi request reprint Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer
    Chris Jones
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 64:3037-45. 2004
    ..These data provide a framework for the interpretation of breast cancer molecular profiling experiments, the identification of potential new diagnostic markers, and development of novel indicators of prognosis...
  56. ncbi request reprint Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis
    Peter T Simpson
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Am J Surg Pathol 29:734-46. 2005
    ..These data further support the hypothesis that CCLs are a nonobligate, intermediary step in the development of some forms of low grade in situ and invasive carcinoma...
  57. pmc APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer
    Rachel Brough
    Cancer Research UK Gene Function and Regulation Group, London, UK
    EMBO J 31:1160-76. 2012
    ....
  58. doi request reprint Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, ICR, 237 Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 132:15-28. 2012
    ....
  59. doi request reprint Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    Genes Chromosomes Cancer 48:351-65. 2009
    ..Given that GI breast cancers harbor a luminal phenotype, our results suggest that if progression from GI to GIII breast cancer does happen, it may preferentially occur in breast cancers of luminal phenotype...
  60. pmc A mouse model of melanoma driven by oncogenic KRAS
    Carla Milagre
    Signal Transduction Team, The Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:5549-57. 2010
    ..These tumors invade and destroy the underlying muscles and cells derived from them can grow as subcutaneous tumors and colonize the lungs of nude mice. These data establish that oncogenic KRAS can be a founder event in melanomagenesis...
  61. ncbi request reprint Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis
    Kay Savage
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res Treat 110:245-56. 2008
    ..The aims of this study were to define the distribution of caveolin 2 (CAV2) in frozen and formalin fixed, paraffin embedded (FFPE) normal breast samples and the significance of CAV2 expression in breast cancer...
  62. doi request reprint Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Pathol 64:130-5. 2011
    ..To evaluate the clinicopathological associations and predictive value of the transcription factor NF-κB in a large series of breast cancer patients treated with neoadjuvant chemotherapy...
  63. doi request reprint Genomic characterisation of acral melanoma cell lines
    Simon J Furney
    Signal Transduction Team, Division of Cancer Biology, Institute of Cancer Research, London, UK
    Pigment Cell Melanoma Res 25:488-92. 2012
    ..Data are available at: http://rock.icr.ac.uk/collaborations/Furney_et_al_2012/...
  64. doi request reprint Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis
    Felipe C Geyer
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Histopathology 60:E115-30. 2012
    ..The aims of this study were to determine whether MGAs harbour genetic alterations and if any such genetic aberrations found in MGAs are similar to those found in matched invasive carcinomas...
  65. pmc Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
    Konstantin J Dedes
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Cell Cycle 10:1192-9. 2011
    ..Here we discuss the evidence that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers...
  66. pmc A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
    Monika Graeser
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Academic Department of Biochemistry, and Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 16:6159-68. 2010
    ....
  67. doi request reprint BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
    Gemma Molyneux
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Cell Stem Cell 7:403-17. 2010
    ..They also demonstrate that when target cells for transformation have the potential for phenotypic plasticity, tumor phenotypes may not directly reflect histogenesis. This has important implications for cancer prevention strategies...
  68. pmc Absence of microsatellite instability in mucinous carcinomas of the breast
    Magali Lacroix-Triki
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
    Int J Clin Exp Pathol 4:22-31. 2010
    ..Our results demonstrate that MSI-high phenotype is remarkably rare in invasive breast cancer, and that, in contrast to mucinous carcinomas of other anatomical sites, MSI is not a common event in mucinous carcinomas of the breast...
  69. ncbi request reprint Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes
    Chris Jones
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Clin Cancer Res 10:5988-97. 2004
    ..Robust characterization of this basal group is necessary if it is to have a major impact on management of patients with breast cancer...
  70. doi request reprint Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas
    David S P Tan
    Department of Gynaecologic Oncology, Royal Marsden Hospital NHS Foundation Trust, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 17:1521-34. 2011
    ..Ovarian clear cell carcinomas (OCCC) are a drug-resistant and aggressive type of epithelial ovarian cancer. We analyzed the molecular genetic profiles of OCCCs to determine whether distinct genomic subgroups of OCCCs exist...
  71. doi request reprint High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform
    Maryou B K Lambros
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Lab Invest 91:1491-501. 2011
    ..In keeping with other highly sensitive assays, further refinement of this technique is necessary to reduce the number of false-positive results...
  72. ncbi request reprint Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research
    David S P Tan
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lab Invest 87:737-54. 2007
    ....
  73. doi request reprint Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma
    Leisl M Packer
    Signal Transduction Team, Section of Cell and Molecular Biology, The Institute of Cancer Research, London, UK
    Pigment Cell Melanoma Res 22:785-98. 2009
    ..This study provides a basis for understanding the molecular processes that are regulated by (V600E)BRAF/MEK signalling in melanoma cells...